Kiniksa Pharmaceuticals International, plc

Good day and thank you for standing by. Welcome to the Connexus Pharmaceuticals' fourth quarter and full year 2023 earnings conference call. At this time, all participants are in a lesson-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations. Please go ahead.

Thank you, Operator. Good morning, everyone, and thank you for joining Connexus Call to discuss our fourth quarter and full year 2023 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investor section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our ARCLPS commercial execution. John Paolini, our Chief Medical Officer, will review the Abby's ProveArt program and recent Phase 2 data. Then Mark Ragosa, our Chief Financial Officer, will review our fourth quarter and full year 2023 financial results. And finally, Sondra will return for closing remarks and to kick off the Q&A session, for which Evan Tesari, our Chief Operating Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors Contained in Our SEC Filing. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I'll review our fourth quarter and full year 2023 financial results today. Consistent execution in both commercial and clinical settings throughout 2023 has put us in a strong position to further advance our business in the year ahead. The Arculus commercialization continues to see meaningful growth with Q4 net product revenue of $71.2 million. putting us at $233.2 million for the past year. We're very encouraged with the commercial execution to date, which is underscored by growing prescriber adoption and increased duration, as well as continued high patient satisfaction and payer approvals. Moving forward, we remain highly focused on reaching even more patients and driving long-term sustained growth with Arclist. Looking to the year ahead, we have guided to ARCLIS sales of between $360 and $380 million, which would represent roughly 59% year-over-year growth at the midpoint. In terms of our pipeline, we recently provided data from the first three cohorts of the Abiprobar Phase II rheumatoid arthritis trial. And data from cohort four, the monthly dosing cohort, are expected in April. Data from this cohort will provide additional dosing insights and are intended to inform future trial design. Based on the data we have evaluated to date, we now expect to advance the asset into a phase 2b trial in a new indication, which will also be announced in April. This next step is already included in our current cash one-way guidance. And with that, I'll turn it over to Ross to review our commercial execution. Ross?